Finally, in the context of pituitary adenoma, ETS2 is involved in inhibition of PRL gene expression (63), and therefore, the decrease of ETS2 mRNA in PRL tumors is consistent with the observed hyperprolactinemia. The gene discussed is PRL; the disease is pituitary gland adenoma.